Clearmind Medicine Inc. has filed a European patent application for novel psychedelic compounds aimed at treating PTSD and other mental health disorders. This move strengthens Clearmind's intellectual property in Europe and aligns with recent U.S. policy encouraging psychedelic therapy research. The global PTSD treatment market is expected to grow to $30.2 billion by 2035, highlighting the commercial potential. Clearmind holds exclusive global rights to develop and commercialize these compounds under a licensing deal with Yissum Research Development Company.
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
The CLARITY Act, a key bill aimed at providing clear federal guidelines for digital assets, is facing a vote shortfall in the Senate with only about 51 confirmed or likely yes votes, below the 60 needed. Republican support remains strong, but Democra...
Bitcoin faces a potential drop to $45,000 by early October 2026, linked to patterns seen in past crypto exchange failures like Mt. Gox and FTX. The planned shutdown of BitMEX signals a possible market capitulation phase, with Bitcoin trading near key...
XRP's exchange activity on Binance has sharply declined, dropping from about 650,000 to 350,000 deposits and withdrawals, signaling reduced selling pressure and increased holding. Meanwhile, the NVT Ratio surged, indicating XRP's market value is grow...
Prediction markets on Kalshi assign a 59% probability that XRP will trade below $1 before the end of 2026, reflecting weakened confidence in a sustained recovery despite a recent modest rebound. XRP has struggled to maintain momentum, repeatedly movi...
